Repligen Corporation (RGEN) Net earnings per share (EPS TTM)
Repligen Corporation is developing advanced bioprocessing systems through large-scale R&D investments, utilizing external partners for the production of standard components while maintaining full control over patents. Revenue stability is based on consistent demand for consumables, as confirmed by GURU.Markets quotes that form this chart. A snapshot of the rolling annual earnings per share clearly demonstrates the business's resilience, where -0.21 serves as the final level mark.
RGEN (Repligen Corp): analytical breakdowns and indicator data
- stock price and consensus target price:
- market capitalization details:
- business book valuation details:
- debt and liquidity details:
Total Debt to Capital Repligen Corporation|RGEN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Repligen Corp.|RGEN - Company Cumulative Debt|Debt to Book Capitalization Ratio Repligen Corporation|RGEN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Repligen|Quick Liquidity repligen.com
- earnings and multiples data:
RGEN - Company Net Income|Expected Profit Repligen Corporation|RGEN - Company Value to Net Income|Forward P/E Multiple Repligen|RGEN - PEG Multiple|Enterprise Value to EBITDA Ratio Repligen Corporation|RGEN - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Repligen|RGEN - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months repligen.com|RGEN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Repligen Corporation
Basic company analysis:RGEN - Repligen Corporation
To find a balance between valuation and business quality, it is essential to evaluate the TTM EPS—the aggregate annual net income per share, which neutralizes the impact of share issuance on profitability. The trend of the rolling annual net income per share reflects the efficiency of Repligen Corporation (RGEN) engineering solutions in biopharmaceuticals, converting technological leadership into adjusted per-share income.
Competing companies
Tempus AI - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year qiagen.com (QGEN)|IONS: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Avidity Biosciences Inc (RNA)|Earnings per share for the last twelve months CRISPR Therapeutics Corp|Earnings per share for the last 12 months WGS (GeneDx Corp)|Net earnings per share for the last 12 months RARE (Ultragenyx Pharmaceutical)|BEAM (beamtx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) SRPT (Sarepta)|TWST - Net earnings per share for the last 12 months|TXG - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Intellia Corp|Stoke Therapeutics (STOK) - Earnings per share for the last twelve months|biolifesolutions.com - Earnings per share for the trailing year|Earnings per share for the last twelve months Wave Life Sciences Ltd.|Maze Therapeutics, Inc. - Earnings per one share for the last 12 months|Earnings per share for the last twelve months Sionna Pharma (SION)|PRME - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Taysha Gene Therapies TSHA|Earnings per share for the trailing year QURE|MeiraGTx - Net earnings per share (EPS TTM)|RGNX - Net earnings per share (EPS TTM)|SLDB (Solid Bio) - Net earnings per share for the last 12 months|OCGN: Earnings per share for the last four quarters|PACB (Pacific Biosciences) - Net earnings per share (EPS TTM)|benitec.com (BNTC) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Design Therapeutics, Inc. (DSGN)|RCKT - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months 4D Molecular Therapeutics Inc FDMT|LXEO: Earnings per share for the last 12 months|KRRO - Earnings per share for the last twelve months|Earnings per share for the trailing year EDIT (editasmedicine.com)|SLN: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year ProQR Therapeutics PRQR|CDXS (Codexis Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Sangamo BioSciences SGMO|Earnings per share for the last twelve months Nautilus Biotechnology (NAUT)|metagenomi.co - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) DTIL (Precision BioSciences, Inc.)|GBIO: Earnings per share for the last 12 months|BOLD - Earnings per share for the last twelve months|XCUR (Exicure, Inc.) - Earnings per share for the last 12 months|IMNN: Net earnings per share (EPS TTM)|Phio Pharmaceuticals Corp. (PHIO) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Mustang Bio Inc|RNAZ: Earnings per share for the trailing year|Net earnings per share (EPS TTM) BNGO|APDN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months bluebird bio, Inc. BLUE|IPA (ImmunoPrecise Antibodies Ltd) - Earnings per one share for the last 12 months|OMGA - Earnings per share for the last twelve months|OMIC: Earnings per share for the last twelve months|RGLS: Net earnings per share (EPS TTM)|SYRS - Net earnings per share for the last four quarters|TBIO (Telesis Bio, Inc.) - Net earnings per share (EPS TTM)|TCON - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) UBX
